(Q46241018)

20 December 2017

title

Phase II study of gefitinib in patients with advanced salivary gland cancers (English)

1 reference

20 December 2017

author

George R Blumenschein

9

object named as

George R Blumenschein

1 reference

20 December 2017

Ana Maria Gonzalez-Angulo

8

object named as

Ana M Gonzalez-Angulo

1 reference

20 December 2017

author name string

John A Jakob

1

1 reference

20 December 2017

Merrill S Kies

2

1 reference

20 December 2017

Bonnie S Glisson

3

1 reference

20 December 2017

Michael E Kupferman

4

1 reference

20 December 2017

Diane D Liu

5

1 reference

20 December 2017

J Jack Lee

6

1 reference

20 December 2017

Adel K El-Naggar

7

1 reference

20 December 2017

publication date

30 March 2015

1 reference

20 December 2017

published in

Head & Neck

1 reference

20 December 2017

volume

37

1 reference

20 December 2017

issue

5

1 reference

20 December 2017

page(s)

644-649

1 reference

20 December 2017

What is new in the management of salivary gland cancers?

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669372

Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669372

Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669372

Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669372

Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669372

Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669372

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669372

Multistage designs for phase II clinical trials: statistical issues in cancer research

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669372

A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669372

Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669372

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669372

Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669372

Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669372

HER2 expression in salivary gland carcinomas: dependence on histological subtype.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669372

Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

15 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FHED.23647

Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study

21 January 2018

1 reference

12 December 2020

A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands

1 reference

12 December 2020

Salivary gland tumors: immunohistochemical study of EGF, EGFR, ErbB-2, FAS and Ki-67

1 reference

12 December 2020

Salivary gland tumours

1 reference

12 December 2020

Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin

1 reference

12 December 2020

Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study

1 reference

12 December 2020

Identifiers

DOI

10.1002/HED.23647

1 reference

20 December 2017

PMCID

5669372

1 reference

20 December 2017

PubMed ID

24585506

1 reference

20 December 2017